The New Semaglutide Options Now Available in the UK

The misconception worth clearing up first: 'new semaglutide' is not a different drug

A lot of the coverage around these updates implies something more radical than what actually happened. Semaglutide is not a new molecule. It has been the active ingredient in Wegovy since the medicine was first licensed in the UK. What changed in 2026 is that two new formats received MHRA approval: a higher-dose injection pen and an oral tablet. The underlying GLP-1 mechanism (slowing gastric emptying, increasing feelings of fullness, reducing appetite) is the same in all of them. So if you've been reading about a 'new semaglutide' and wondering whether it's a different drug altogether, the honest answer is: it's a dose increase and a new delivery route, not a new medicine. That matters because it means the existing evidence base, safety profile, and prescribing framework all carry over.

The NHS medicines page for semaglutide covers the shared pharmacology and side-effect profile clearly, and it's a useful starting point if you want to understand what the drug class does before looking at what's new.

The 7.2mg Wegovy pen: what a higher injection dose offers

For several years, 2.4mg was the standard maintenance dose for Wegovy injections. The MHRA approved 7.2mg as a maintenance option in January 2026, and on 14 April 2026 approved a dedicated single-dose pen for it, one pre-set weekly injection with an auto-dosing mechanism and a covered needle that locks after use. The starting dose remains 0.25mg; the prescriber titrates upward, with 7.2mg as the ceiling. This higher dose is licensed for adults with a BMI of 30 or above. It is not indicated for the cardiovascular risk-reduction use case, and it is not for people below that BMI threshold.

Why does the dose increase matter? Trial data at 7.2mg reported around 20.7% average weight loss over 72 weeks, narrowing the gap with tirzepatide 15mg results, which is clinically significant. If you want a fuller picture of how Wegovy's evidence stacks up, our Wegovy overview covers the trial data and eligibility criteria in detail.

One thing to note about availability: the specific pen format your prescriber recommends depends on clinical factors and what is in supply at the time. A consultation is the right place to confirm which dose and format is appropriate for you.

Oral semaglutide tablets: what the UK's first licensed GLP-1 weight-loss tablet involves

The tablet approval on 11 June 2026 is genuinely new territory. The UK was the first country in Europe to license an oral GLP-1 medicine for weight management, and for people who want to avoid injections, it changes the conversation. The tablets use semaglutide combined with an absorption enhancer called SNAC, which allows the medicine to cross the stomach lining into the bloodstream. The dose ladder runs 1.5mg, 4mg, 9mg, and up to a 25mg maintenance dose, with at least one month at each level. People already stable on the 2.4mg weekly injection may move directly to 25mg tablets, subject to prescriber assessment.

Taking them correctly matters more than with the injection. The tablet is taken first thing in the morning on an empty stomach, with a small amount of plain water, roughly up to 120ml. You then wait at least 30 minutes before any food, coffee, or other oral medicines. No refrigeration is needed, which makes the tablet format easier to manage while travelling. Phase 3 trial data (OASIS 4, 64 weeks, 307 adults) reported an average of around 13.6% weight loss compared to around 2.4% with placebo; among participants who stayed fully adherent to treatment, average loss reached approximately 17%. The most common side effects in the trial were gastrointestinal, reported in around 74% of participants taking the tablet, typically mild to moderate and settling over time. For a closer look at cost context for these treatments, our Wegovy cost page sets out what private treatment typically involves.

Eligibility, access, and what a prescriber actually considers

Both new formats are prescription-only medicines. That is not a formality, it reflects the fact that semaglutide is not appropriate for everyone, and the right dose and format depend on your individual health picture. The licensed eligibility for weight management is adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes. Under-18s are not licensed for these treatments. Semaglutide is not recommended during pregnancy, while breastfeeding, or for those actively trying to conceive. A prescriber will also look at your medication history, any conditions that might affect suitability, and your starting point before recommending a format and dose.

Neither the 7.2mg pen nor the oral tablet is currently available through the NHS; a NICE appraisal process would need to happen first. Private prescription is currently the only route. For more on how recent updates to the semaglutide licence fit into the broader picture, the latest semaglutide news page tracks MHRA and NHS developments as they happen. You can also read more about what's new with Wegovy specifically, or explore the new version of semaglutide in more depth. Our weight-loss treatment overview is a helpful place to compare options if you're still at the research stage.

If you'd like to find out whether you're a good candidate for any of these treatments, speak to our prescribers through a free consultation, a real clinician reviews every application the same day.